# Efficacy and Safety of Cipros 20 Association on Dyslipidemia Treatment

Study · id `cardio:ct-nct03540355` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03540355](<https://clinicaltrials.gov/study/NCT03540355>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03540355

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 406 participants.

## Technical summary

Registry record NCT03540355. Randomized; double masking; primary purpose treatment. Start 2021-03-02 (actual); primary completion 2025-01-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 406 participants (enrolled count; ClinicalTrials.gov record NCT03540355, source copy `cardio:ctgov-nct03540355-2026-01-09`, retrieved 2026-10-31)
- Started: 2021-03-02 (actual) (ClinicalTrials.gov record NCT03540355, source copy `cardio:ctgov-nct03540355-2026-01-09`, retrieved 2026-10-31)
- Primary completion: 2025-01-23 (actual) (ClinicalTrials.gov record NCT03540355, source copy `cardio:ctgov-nct03540355-2026-01-09`, retrieved 2026-10-31)
- Completion: 2025-01-23 (actual) (ClinicalTrials.gov record NCT03540355, source copy `cardio:ctgov-nct03540355-2026-01-09`, retrieved 2026-10-31)
- Countries: Brazil (ClinicalTrials.gov record NCT03540355, source copy `cardio:ctgov-nct03540355-2026-01-09`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03540355-2026-01-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of Cipros 20 Association on Dyslipidemia Treatment
- Acronym: CIPROS20
- Condition: Dyslipidemias
- Intervention (Drug): Cipros 20 association
- Intervention (Drug): Crestor 20 mg
- Lead sponsor: EMS
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

## Provenance

Content hash: d973f9ce5ddaa1d8f159a3f3b46a0b207f65b5b458654917568ee65e9086abab
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
